Basic Description

Synonyms	DTXSID101138251 \| GTPL7573 \| MFCD28167769 \| N-(2-cyano-3,12-dioxo-28-noroleana-1,9(11)-dien-17-yl)-2,2-difluoropropanamide \| omaveloxolona \| AKOS037648676 \| N-((4aS,6aR,6bS,8aR,12aS,14aR,14bS)-11-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-1,2,3,4,4a,
Specifications & Purity	Moligand™
Grade	Moligand™
Action Type	ACTIVATOR
Mechanism of action	Nuclear factor erythroid 2-related factor 2 activator

Associated Targets(Human)

NFE2L2 Tchem Nuclear factor erythroid 2-related factor 2 (0 Activities)

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

HT-29 (80576 Activities)

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

L929 (3802 Activities)

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

rep Replicase polyprotein 1ab (378 Activities)

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Mechanism of Action	Action Type	target ID	Target Name	Target Type	Target Organism	Binding Site Name	References

IUPAC Name	N-[(4aS,6aR,6bS,8aR,12aS,14aR,14bS)-11-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-1,3,4,5,6,7,8,8a,14a,14b-decahydropicen-4a-yl]-2,2-difluoropropanamide
INCHI	InChI=1S/C33H44F2N2O3/c1-27(2)11-13-33(37-26(40)32(8,34)35)14-12-31(7)24(20(33)17-27)21(38)15-23-29(5)16-19(18-36)25(39)28(3,4)22(29)9-10-30(23,31)6/h15-16,20,22,24H,9-14,17H2,1-8H3,(H,37,40)/t20-,22-,24-,29-,30+,31+,33-/m0/s1
InChi Key	RJCWBNBKOKFWNY-IDPLTSGASA-N
Canonical SMILES	N#CC1=C[C@@]2(C)[C@H](C(C1=O)(C)C)CC[C@@]1(C2=CC(=O)[C@H]2[C@@]1(C)CC[C@@]1([C@H]2CC(C)(C)CC1)NC(=O)C(F)(F)C)C
Isomeric SMILES	C[C@@]12CC[C@]3(CCC(C[C@H]3[C@H]1C(=O)C=C4[C@]2(CC[C@@H]5[C@@]4(C=C(C(=O)C5(C)C)C#N)C)C)(C)C)NC(=O)C(C)(F)F
PubChem CID	71811910

PubChem CID	71811910
Wikipedia	RTA 408

Enter Lot Number to search for COA:

1. Reisman SA, Lee CY, Meyer CJ, Proksch JW, Ward KW. (2014) Topical application of the synthetic triterpenoid RTA 408 activates Nrf2 and induces cytoprotective genes in rat skin.. Arch Dermatol Res, 306 (5): (447-54). [PMID:24362512] [10.1021/op500134e]
2. Reisman SA, Lee CY, Meyer CJ, Proksch JW, Sonis ST, Ward KW. (2014) Topical application of the synthetic triterpenoid RTA 408 protects mice from radiation-induced dermatitis.. Radiat Res, 181 (5): (512-20). [PMID:24720753] [10.1021/op500134e]
3. Reisman SA, Gahir SS, Lee CI, Proksch JW, Sakamoto M, Ward KW. (2019) Pharmacokinetics and pharmacodynamics of the novel Nrf2 activator omaveloxolone in primates.. Drug Des Devel Ther, 13 (13): (1259-1270). [PMID:31118567] [10.1021/op500134e]
4. Ghanekar SD, Miller WW, Meyer CJ, Fenelon KJ, Lacdao A, Zesiewicz TA. (2019) Orphan Drugs In Development For The Treatment Of Friedreich's Ataxia: Focus On Omaveloxolone.. Degener Neurol Neuromuscul Dis, 9 (13): (103-107). [PMID:31686946] [10.1021/op500134e]
5. Profeta V, McIntyre K, Wells M, Park C, Lynch DR. (2023) Omaveloxolone: an activator of Nrf2 for the treatment of Friedreich ataxia.. Expert Opin Investig Drugs, 32 (1): (5-16). [PMID:36708320] [10.1021/op500134e]
6. Li W, Kong AN. (2009) Molecular mechanisms of Nrf2-mediated antioxidant response.. Mol Carcinog, 48 (2): (91-104). [PMID:18618599] [10.1021/op500134e]

Determine the necessary mass, volume, or concentration for preparing a solution.

Determine the dilution needed to prepare a stock solution.

SKU	Size	Availability	Price	Qty
O612486-5mg	5mg	Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding.	$1,334.90
O612486-25mg	25mg	Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding.	$2,001.90